CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer

PURPOSE: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only two years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Michaels, Alex D., Newhook, Timothy E., Adair, Sara J., Morioka, Sho, Goudreau, Bernadette J., Nagdas, Sarbajeet, Mullen, Matthew G., Persily, Jesse B., Bullock, Timothy N. J., Slingluff, Craig L., Ravichandran, Kodi S., Thomas Parsons, J., Bauer, Todd W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296745/
https://ncbi.nlm.nih.gov/pubmed/29288236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2283
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller